

# CITATION REPORT

List of articles citing

## Opicapone: A Review in Parkinson's Disease

DOI: 10.1007/s40263-020-00778-6  
CNS Drugs, 2021, 35, 121-131.

**Source:** <https://exaly.com/paper-pdf/82898035/citation-report.pdf>

**Version:** 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
11	A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , <b>2021</b> , 394, 839-852	3.4	2
10	Redefining the strategy for the use of COMT inhibitors in Parkinson's disease: the role of opicapone. <i>Expert Review of Neurotherapeutics</i> , <b>2021</b> , 21, 1019-1033	4.3	4
9	Imidazole hydrochloride promoted synthesis of 3,5-disubstituted-1,2,4-oxadiazoles. <i>Tetrahedron</i> , <b>2021</b> , 100, 132496	2.4	0
8	Opicapone Protects Against Hyperhomocysteinemia-Induced Increase in Blood-Brain Barrier Permeability. <i>Neurotoxicity Research</i> , <b>2021</b> , 39, 2018-2028	4.3	0
7	Novel therapeutic interventions for combating Parkinson's disease and prospects of Nose-to-Brain drug delivery. <i>Biochemical Pharmacology</i> , <b>2021</b> , 195, 114849	6	3
6	Opicapone Use in Clinical Practice across Germany: A Sub-Analysis of the OPTIPARK Study in Parkinson's Disease Patients with Motor Fluctuations.. <i>European Neurology</i> , <b>2022</b> , 1-9	2.1	0
5	Opicapone in UK clinical practice: effectiveness, safety and cost analysis in patients with Parkinson's disease.. <i>Neurodegenerative Disease Management</i> , <b>2022</b> ,	2.8	0
4	Opicapone Improves Global Non-Motor Symptoms Burden in Parkinson's Disease: An Open-Label Prospective Study.. <i>Brain Sciences</i> , <b>2022</b> , 12,	3.4	2
3	Developmental and behavioral toxicity assessment of opicapone in zebrafish embryos. <b>2023</b> , 249, 114340		0
2	The real-life effect of catechol-O-methyltransferase inhibition on non-motor symptoms in levodopa-treated Parkinson's disease: opicapone versus entacapone.		0
1	Radiolabeling fingolimod with technetium-99m and evaluating its biological affinity by in vitro method.		0